Anthony Barron is speaking during the symposium on the topic of “Presentation on the Value of Personalized Medicines.”
For more information on this event, click here.
Government Scorekeepers Likely Underestimate the Impact of Lower Drug Costs Now Act (H.R.3) on Investment in Innovative Medicines: Brief
The Congressional Budget Office (CBO), which is charged with calculating the costs of potential legislation to guide policymaking, estimated that if H.R.3 were...